Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Shingrix (Zostavax) Market Grown from 2024 to 2025?
In recent years, the Shingrix (Zostavax) market has seen a growth of XX (HCAGR). The market’s size is forecasted to increase from $XX million in 2024 to $XX million in 2025 with a compound annual growth rate (CAGR) of XX%. The past growth can be accredited to the enhanced adoption of vaccines, escalated need for educational drives, more attention given to preventive healthcare, an uptick in initiatives for patient education and advocacy, along with an improvement in insurance coverage for immunization.
What Growth Rate Is Anticipated for the Shingrix (Zostavax) Market in the Coming Years?
The market size of Shingrix (Zostavax) is projected to experience a XX (FCAGR) increase in the coming years, with projections showing it will reach a worth of $XX million by 2029 with a compound annual growth rate (CAGR) of XX%. The anticipated expansion over the forecast period can be linked to factors such as the growth in the geriatric population, a surge in herpes zoster cases, an increase in chickenpox incidents, heightened disease prevalence, and improved understanding of shingles and related complications. Significant trends during the forecast period consist of revolutionary recombinant vaccines, advancements in the development of vaccines, a focus shift towards disease prevention rather than treatment, AI-driven research and development of vaccines, and enhanced identification of biomarkers for susceptibility to shingles.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20264&type=smp
Who Are the Leading Companies in the Shingrix (Zostavax) Market?
Major companies operating in the shingrix (zostavax) market are GSK plc
What Are the Key Drivers of the Shingrix (Zostavax) Market?
The escalating acceptance of vaccines is anticipated to boost the expansion of the shingrix (zostavax) market. Vaccination, the process in which a vaccine is given to stimulate the body’s immune system to identify and combat specific pathogens, is gaining popularity due to a heightened awareness about its effectiveness in disease prevention, curtailing disease burden, and the production of safe and easily available vaccines. Widespread acceptance is also driven by public health campaigns, enhanced healthcare infrastructure, and international vaccination efforts. Shingrix (Zostavax) proves to be beneficial in vaccination, providing significant protection against shingles and its related complications. It is especially advantageous for adults aged 50 and above, considerably mitigating the risk of shingles recurrence and post-herpetic neuralgia. For example, in May 2024, a study by the Journal of the American Medical Association (JAMA), a US-based peer-reviewed medical journal, showed that shingles vaccinations under Medicare Part D grew by 46% the year following the implementation of the IRA policy in January 2023. Furthermore, in 2022, as per the Australian Government Department of Health and Aged Care, COVID-19 vaccines were ensured to be available to all Australians free of charge. By mid-2022, over 34 million primary vaccines and boosters had been given with a significant role of general practices in the rollout, particularly in rural regions. Thus, the increasing acceptance of vaccines is propelling the growth of the shingrix (zostavax) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20264&type=smp
What Are the Key Market Segments in the Shingrix (Zostavax) Industry?
The shingrix (zostavax) market covered in this report is segmented –
1) By Formulation: Recombinant Vaccine (Shingrix); Live Attenuated Vaccine (Zostavax)
2) By Indication: Shingles Prevention; Post-Herpetic Neuralgia
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy
What Are the Latest Trends in the Shingrix (Zostavax) Market?
One significant trend in the Shingrix (Zostavax) market is the creation of innovative products like non-live, recombinant subunit adjuvanted vaccines aimed at enhancing the effectiveness of vaccines and tackling immune system decline in sensitive populations due to age. A non-live, recombinant subunit adjuvanted vaccine is a vaccine that incorporates distinct protein elements of a pathogen and an adjuvant to boost the immune response. In September 2024, UK-based biopharmaceutical firm GSK plc launched Shingrix, a vaccine for shingles. The Recombinant Zoster Vaccine (RZV) is a non-live vaccine that provides up to 97% prevention against shingles and post-herpetic neuralgia. It is engineered for adults who are 50+ years old as well as immunocompromised individuals aged 18+, delivered intramuscularly in two doses. RZV demonstrated up to 97% effectiveness in adults 50 or older through three years according to the ZOE-50 study, and recent findings showed over 80% effectiveness 6-10 years after the vaccination.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/shingrix-zostavax-global-market-report
What Are the Key Regional Markets in the Shingrix (Zostavax) Industry?
North America was the largest region in the shingrix (zostavax) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingrix (zostavax) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20264
This Report Delivers Insight On:
1. How big is the shingrix (zostavax) market, and how is it changing globally?
2. Who are the major companies in the shingrix (zostavax) market, and how are they performing?
3. What are the key opportunities and risks in the shingrix (zostavax) market right now?
4. Which products or customer segments are growing the most in the shingrix (zostavax) market?
5. What factors are helping or slowing down the growth of the shingrix (zostavax) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model